Table 10.
Changes in the hepatic glucose-regulating enzyme activities in NFD or HFD supplied mice.
| Items Groups | Glucokinase (nM/min/mg Protein) | Glucose-6-phosphatase (nM/min/mg Protein) | PEPCK (nM/min/mg Protein) |
|---|---|---|---|
| Controls | |||
| Intact | 2.8 ± 0.3 | 117.9 ± 12.8 | 2.0 ± 0.3 |
| HFD | 2.0 ± 0.2 a | 175.0 ± 14.3 a | 4.3 ± 0.6 a |
| Reference | |||
| Simvastatin | 2.1 ± 0.3 a | 170.4 ± 22.6 a | 4.0 ± 1.0 a |
| Metformin | 2.5 ± 0.2 bc | 132.9 ± 11.6 bc | 2.7 ± 0.5 bc |
| GT 400 mg/kg | 2.3 ± 0.2 ad | 148.8 ± 12.3 ac | 3.5 ± 0.4 ac |
| fGT treated | |||
| 400 mg/kg | 2.7 ± 0.2 ce | 118.6 ± 11.1 ce | 2.2 ± 0.2 ce |
| 200 mg/kg | 2.7 ± 0.2 ce | 126.4 ± 9.6 ce | 2.5 ± 0.4 bce |
| 100 mg/kg | 2.5 ± 0.1 bcf | 133.0 ± 10.7 bcf | 2.7 ± 0.3 ace |
Values are expressed as mean ± SD of eight mice. NFD, normal fat pellet diet; HFD, high fat diet; GT, green tea extracts; fGT, Aquilariae lignum-fermented green tea extracts; PEPCK, Phosphoenolpyruvate carboxykinase. Simvastatin and metformin were administrated at dose levels of 10 and 250 mg/kg, respectively. a p < 0.01 and b p < 0.05 as compared with intact control; c p < 0.01 and d p < 0.05 as compared with HFD control; e p < 0.01 and f p < 0.05 as compared with GT 400 mg/kg.